Atreca, a US-based immune-focused medicine developer based on research at Stanford University, completed an oversubscribed $125m series C round today led by an undisclosed existing investor described as a healthcare-focused fund. The round included Tavistock Group’s Boxer Capital unit, Wellington Management Company, Cormorant Asset Management, Aisling Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management. Atreca is developing drugs based on the responsiveness of the human body’s immune system. Its lead program is focused on cancer and its lead candidate, ATRC-101, is being developed to target breast, lung and colon tumours. The company was co-founded by Lawrence Steinman, the George Zimmermann professor of neurology and neurological sciences and paediatrics in Stanford University’s School of Medicine. John Orwin, Atreca’s president and chief executive, said: “This funding enables us to broaden and accelerate our discovery and pipeline generation efforts and to move our first candidate into clinical development. “This first candidate, generated by our unique discovery engine and via our proprietary Immune Repertoire Capture technology, represents a novel and potentially fundamental new class of oncology immunotherapeutics. The round increased Atreca’s overall funding to $226m according to press releases and regulatory filings, the company having received $6m from Bill & Melinda Gates Foundation in 2012. Pharmaceutical firm GlaxosSmithKline and Bill & Melinda Gates Foundation joined Mission Bay Capital for Atreca’s $56m series A round in 2015, which was led by an unnamed healthcare-focused fund. Wellington Management Company co-led a $35m series B round for the company with an undisclosed healthcare-focused fund in August 2017, investing alongside Cormorant Asset Management and undisclosed new and existing backers. – A version of this article first appeared on our sister site, Global Corporate Venturing.
Atreca carries on funding streak
Sep 12, 2018 •
LEADERSHIP SOCIETY
Informing, connecting, and transforming the global corporate venture capital ecosystem.The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Halo has researchers on speed dial for corporates
Halo has researchers on speed dial for corporates
How does a corporate find the right university researcher or startup when it's trying to solve a critical problem? Halo has the answer.
How Basel supercharged its spinout rate
How Basel supercharged its spinout rate
Basel has quietly built a life sciences ecosystem that’s becoming hard to ignore.
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
Crumbling system, fragile lives: can spinouts help in the senior care crisis?
From a chest-worn device to help with Parkinson's symptoms to stress measuring socks — here are the spinouts providing support for senior citizens.
Events
Webinar: Innovate to heal - What does the hospital of the future look like?
Apr 10, 2024
Online
Online
Events
GCV Institute: Landing the Value of Corporate Venturing
May 6 -
May 9, 2024
Online
May 9, 2024
Online
Events
GCV Institute: CVC Investment Programs
May 21 -
May 22, 2024
Online
May 22, 2024
Online
Events
GCV Symposium 2024
Jun 24 -
Jun 26, 2024
London (UK)
Jun 26, 2024
London (UK)
Events
Corporate Venture in Brasil 2024 – International Delegation to Brazil
Oct 28 -
Oct 30, 2024
São Paulo (Brazil)
Oct 30, 2024
São Paulo (Brazil)
Top News
test reg